DGNOF (Diagnos) Valuation Rank


DGNOF Diagnos Inc DGNOF
16 GF Score
Price $0.18
GF Value $0.05
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Diagnos Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Diagnos Valuation Rank Related Terms

DGNOF
16GF Score
Diagnos Inc DGNOF
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Diagnos (DGNOF) Overvalued in 2026?

Based on GuruFocus' analysis, Diagnos stock appears to be overvalued. The current stock price of $0.18 is trading 253.9% above its estimated GF Value™ of $0.05. GuruFocus considers Diagnos to be Significantly Overvalued.

Key valuation signals for DGNOF:

  • Valuation Rank:
  • GF Value™: $0.05 vs. price of $0.18 (253.9% above fair value)
  • GF Score™: 16/100 with 5 warning signs

No single metric tells the full story. See the DGNOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diagnos Business Description

Other Exchanges ADK:Canada
Address 7005 Taschereau Boulevard, Suite 265, Brossard, Longueuil, QC, CAN, J4Z 1A7
Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in a single business segment of Healthcare services. The company has a business presence in Canada, United States of America, Mexico, Chile and others. The company's key revenue is derived from Canada.
16GF Score

Get the complete analysis for DGNOF

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.18
Price
$0.05
GF Value